CIRB Studies

Below is the current list of studies covered by the CIRB. Participants should refer to ClinicalTrials.gov for general information about clinical trials. Institutions should refer to the Clinical Trials Support Unit (CTSU) website  for enrollment requirements and accrual status information. 

Study documents approved after July 1, 2013 are available to participating institutions for covered studies on the CTSU website. To request documents approved before July 1, 2013, participating institutions can contact the CIRB Helpdesk.

Review CIRB
Study Number Network Study Title CIRB
10720 ETCTN Phase 1b study of Pidnarulex and Trastuzumab Deruxtecan in patients with HER2 expressing Solid Tumors Adult CIRB - Early Phase Emphasis
10721 ETCTN Neoadjuvant Chemotherapy with or without Cemiplimab (REGN2810) in Sinonasal Squamous Cell Carcinoma: A Randomized Phase 2 Study Adult CIRB - Early Phase Emphasis
10727 ETCTN Phase 1b Study of Teclistamab in Relapsed/Refractory Plasmablastic Lymphoma Adult CIRB - Early Phase Emphasis
10732 ETCTN Phase I Trial of ATR Inhibitor Camonsertib Combined with Stereotactic Body Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma Adult CIRB - Early Phase Emphasis
10733 ETCTN Phase I/II study of the MEK inhibitor Selumetinib plus DS-8201a (trastuzumab deruxtecan) in KRAS-mutant, HER2-expressing pancreatic ductal adenocarcinoma Adult CIRB - Early Phase Emphasis
10741 ETCTN A Phase 2 Study of Microsatellite Stable Colorectal Cancer (Stage 2 or 3) with Radiographic Occult Molecular Residual Disease Treated with Botensilimab (AGEN1181; Bot) plus Balstilimab (AGEN2034, Bal) After Established Definitive Therapy (COMBAT Study) Adult CIRB - Early Phase Emphasis
10743 ETCTN Pilot Phase II Trial Evaluating Safety and Feasibility of Neoadjuvant Botensilimab and Balstilimab in Clear Cell Renal Cell Carcinoma (NEO RoBOT) Adult CIRB - Early Phase Emphasis
8329 ETCTN A Phase I/II Trial of ABT-888, an Inhibitor of Poly(ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients with Solid Tumors (Phase I) and Relapsed Ovarian Cancer or Primary Peritoneal Cancer (Phase II) After Prior Platinum Containing First-Line Chemotherapy Adult CIRB - Early Phase Emphasis
9149 ETCTN Molecular Profiling-based Assignment of Cancer Therapy for Patients With Advanced Solid Tumors Adult CIRB - Late Phase Emphasis
9466 ETCTN Phase I/II study of dabrafenib, trametinib, and navitoclax in BRAF mutant melanoma (Phase I and II) and other solid tumors (Phase I only) Adult CIRB - Early Phase Emphasis